公开(公告)号：EP3221312A2

公开(公告)日：2017-09-27

申请号：EP15861618.5

申请日：2015-11-19

申请人： GlaxoSmithKline LLC

发明人： BLUM, Charles A. ,  CALDWELL, Richard Dana ,  CASAUBON, Rebecca ,  DISCH, Jeremy S. ,  FOX, Ryan Michael ,  KOPPETSCH, Karsten ,  MILLER, William, Henry ,  NG, Pui, Yee ,  OALMANN, Christopher ,  PERNI, Robert, B. ,  SZCZEPANKIEWICZ, Bruce G. ,  WHITE, Brian H.

IPC分类号： C07D471/04 ,  C07D513/18

CPC分类号： C07D471/18 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/551 ,  A61K45/06 ,  A61P17/10 ,  C07D487/04 ,  C07D513/18 ,  C07D519/00

摘要： The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

摘要翻译： 本发明涉及新的取代的桥联脲化合物，相应的类似物，药物组合物及其使用方法。 本发明的瑟土因调节性化合物可以用于增加细胞的寿命，并且治疗和/或预防各种各样的疾病和病症，包括但不限于例如与以下疾病或病症有关的疾病或病症 衰老或压力，糖尿病，肥胖症，神经退行性疾病，心血管疾病，凝血障碍，炎症，癌症和/或潮红以及将受益于线粒体活性增加的疾病或病症。 本发明还涉及包含沉默调节蛋白调节化合物与另一种治疗剂组合的组合物。